Lineage Cell Therapeutics, Inc. LCTX
Set alert
At close · Oct 30
After hours · Oct 30, 5:02 PM ET
- YTD
- -40.12%
- 1 year
- -45.65%
- Open
- 1.04
- Prev close
- 1.03
- Mkt cap
- 252.91M
- Vol
- 1.17M
- Avg vol
- 1.25M
- EPS
- -0.19
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.9821
- High
- 1.05
- Forward P/E
- -3.66
- Beta
- 1.28
- Short ratio
- 35.21
- Inst. own
- 50.56%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.7364
- 200-d avg
- 0.96025
- 1y target
- 4.83
News
3 days ago businesswire.com
Lineage Provides Update on ReSonance® Program for Hearing Loss
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel,…
2 weeks ago benzinga.com
Transcript: Lineage Cell Therapeutics Q2 2026 Earnings Conference Call
On Thursday, Lineage Cell Therapeutics (AMEX:LCTX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by…
1 month ago defenseworld.net
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Climb 8.7% – Here’s What Happened
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) shares were up 8.7% during trading on Friday. The company traded as high as $1.04 and last traded at $1.03. Approximately…
1 month ago businesswire.com
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--AlloSCOPE 5D Patent Release.
2 months ago marketbeat.com
Lineage Cell Therapeutics Q2 Earnings Call Highlights
Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease,…
2 months ago seekingalpha.com
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.01 per share a year ago.
2 months ago businesswire.com
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q2 2026 Earnings Release.
3 months ago marketbeat.com
Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject' Cell Therapy Plan
Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being…
3 months ago seekingalpha.com
Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript
-
3 months ago benzinga.com
Lineage Cell Therapeutics Updates COR1 Corneal Cell Transplant Program; Highlights Scalable Allogeneic Production Via AlloSCOPE Platform And Plans Conference Call Today
Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PTCOR1 Aims to Provide an "Off the Shelf" Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial DiseaseUtilizes…
3 months ago businesswire.com
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel,…
3 months ago businesswire.com
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf”…
-
4 months ago benzinga.com
Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call
On Tuesday, Lineage Cell Therapeutics (AMEX:LCTX) discussed first-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to…
5 months ago marketbeat.com
Lineage Cell Therapeutics Q1 Earnings Call Highlights
Lineage Cell Therapeutics NYSEAMERICAN: LCTX reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program…
5 months ago seekingalpha.com
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
5 months ago zacks.com
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
-
5 months ago benzinga.com
Lineage Cell Therapeutics Q1 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.725M Miss $3.602M Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent decrease over losses of…
5 months ago businesswire.com
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf”…
6 months ago businesswire.com
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf”…
6 months ago businesswire.com
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf”…
6 months ago businesswire.com
Lineage Announces Formation of Scientific Advisory Board
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel…
6 months ago prnewswire.com
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned
6 months ago benzinga.com
Service Properties Trust, ConocoPhillips And Other Big Stocks Moving Lower In Monday's Pre-Market Session
US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market trading. Other decliners: MGRT, UP, CDZI, LCTX, KEP, AUTL, EOG, ANGX, COP.
7 months ago defenseworld.net
Defender Capital LLC. Buys Shares of 6,829,099 Lineage Cell Therapeutics, Inc. $LCTX
Defender Capital LLC. bought a new stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) in the undefined quarter, according to its most recent disclosure with the Securities and…
-
7 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.
-
7 months ago benzinga.com
Lineage Cell Therapeutics Expands Cell Transplant Pipeline With COR1
New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing ExpertiseFuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
7 months ago benzinga.com
Lineage Cell Therapeutics Files Prospectus To Offer Up To $100M In Common Shares, Preferred Shares, Debt, And Warrants
$100,000,000 Common SharesPreferred SharesDebt SecuritiesWarrants From time to time, we may offer up to $100,000,000 of any combination of the securities described in this prospectus in one or more…
-
7 months ago benzinga.com
Lineage Cell Therapeutics Files $60M ATM Share Offering Prospectus Supplement
Other Events.On March 11, 2026, Lineage Cell Therapeutics, Inc. (the "Company") filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement dated March 11, 2026 (the…
-
8 months ago benzinga.com
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Raises Price Target to $3
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and raises the price target from $2 to $3.
8 months ago benzinga.com
Lineage Cell Therapeutics Q4 Earnings Summary & Key Takeaways
Lineage Cell Therapeutics Q4 Earnings Summary & Key Takeaways
-
8 months ago benzinga.com
Lineage Cell Therapeutics Q4 EPS $0.00 Beats $(0.05) Estimate, Sales $6.600M Beat $2.577M Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.05) by 108.51 percent. This is a 120 percent increase over losses…
-
8 months ago benzinga.com
A Look Ahead: Lineage Cell Therapeutics's Earnings Forecast
A Look Ahead: Lineage Cell Therapeutics's Earnings Forecast
11 months ago benzinga.com
Snowflake, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Snowflake, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
-
11 months ago benzinga.com
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.
-
11 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Lineage Cell Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. analyst Joseph Pantginis maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.
-
11 months ago benzinga.com
Lineage Cell Therapeutics Sold 12M Common Shares To Janus Henderson Investors At A Purchase Price Of $1.75/Share In A Block Transaction Under Its ATM Offering Program; Company Received $21M In Gross Proceeds
On November 12, 2025, Lineage Cell Therapeutics, Inc. (the "Company") sold 12,000,000 common shares to Janus Henderson Investors at a purchase price of $1.75 per share in a block transaction under…
-
12 months ago benzinga.com
Lineage Cell Therapeutics Q3 EPS $(0.13) Misses $(0.02) Estimate, Sales $3.681M Beat $2.300M Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.02) by 441.67 percent. This is a 550 percent decrease over…
12 months ago benzinga.com
Earnings Scheduled For November 6, 2025
Earnings Scheduled For November 6, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
Lineage Cell Therapeutics Announces Launch Of A New Islet Cell Transplant Program Targeting Type 1 Diabetes
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions,…
-
1 year ago benzinga.com
5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know
5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know
-
1 year ago benzinga.com
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.
-
1 year ago benzinga.com
Lineage And William Demant Collaborate Through Investment To Develop ReSonance For Hearing Loss
Three-year term intended to advance preclinical development of ReSonanceUp to $12 million of development costs to be contributed by William Demant Invest
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.
-
1 year ago benzinga.com
Update: Lineage Cell Therapeutics Q2 Adj. EPS $(0.07) Misses $(0.03) Estimate, Sales $2.765M Beat $1.472M Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 159.26 percent. This is a 133.33 percent decrease over…